Why Is Jardiance So Expensive?
By BetterBuyRx Editorial Team
Written for cost and savings education only, not medical advice, and not medically reviewed. Always confirm details with your doctor or pharmacist. See our methodology.
Last updated
Jardiance (empagliflozin) listed at $573 for a 30-day supply in 2023, per CMS, and unlike Eliquis, it doesn't even have an FDA-approved generic waiting in the wings at U.S. pharmacies. Its price is the textbook output of three compounding forces: intact patent protection, demand that expanded far beyond its original diabetes indication, and the list-price-and-rebate machinery that governs U.S. brand pricing. Here's each force, and the two developments that actually bend the curve.
Force 1: Patents with years left to run
Empagliflozin was approved in 2014, making it a relatively young blockbuster. Its core patents remain in force into the late 2020s, and no generic can be sold at U.S. pharmacies until they expire or fall in litigation. Compare the two ends of the lifecycle in our own July 2026 verified data: Jardiance's cheapest verified source was $158.99/month (international mail-order), while post-patent simvastatin was $3.50, a 45x gap explained almost entirely by where each molecule sits on the patent clock.
Force 2: A drug that outgrew its label
Jardiance launched as a type 2 diabetes drug. Since then its approved uses have expanded to heart failure and chronic kidney disease (MedlinePlus lists all three), multiplying the eligible patient population. In most markets, surging demand meets rising supply and prices fall; in a patent-protected market, surging demand meets a fixed monopoly and prices hold. SGLT2 inhibitors as a class (Jardiance, Farxiga, and peers) are all on-patent brands, so even "switching within the class" doesn't reach a cheap option.
Force 3: The rebate treadmill
U.S. brand drugs carry two prices: the list price the manufacturer publishes (and cash payers face) and the net price after confidential rebates paid to pharmacy benefit managers for formulary placement. The FTC's interim PBM report documents how this structure can push list prices upward; rebates are a percentage of list, so everyone in the chain except the patient can benefit from a higher sticker. It's why coinsurance and deductible-phase bills for Jardiance sting even for insured patients, and why our general explainer why is my prescription so expensive spends so much time on PBMs.
What bends the curve: negotiation now, patent cliff later
Medicare negotiation (now). Jardiance was in the first negotiated cohort: $197 per 30-day supply effective 2026, 66% below the 2023 list price of $573, per CMS. With 2026's $2,100 Part D out-of-pocket cap (details here), Medicare enrollees finally have a bounded Jardiance budget.
The patent cliff (later). When empagliflozin's exclusivity ends, expect the familiar sequence: first one or two generics at modest discounts, then a crowd, then commodity pricing within a few years. No credible firm date exists yet; distrust any site that quotes one.
Until then, cash payers have three levers, all covered with July 2026 verified numbers in Jardiance cost without insurance: Boehringer Ingelheim's patient assistance program for eligible uninsured patients, the manufacturer savings card for the commercially insured, and international mail-order pharmacies ($158.99 to $199/month verified July 2026). And keep the rest of the regimen cheap: metformin was $3.95 that month; comparison in metformin vs. Jardiance cost.
Frequently asked questions
Why does Jardiance cost so much?
Jardiance is a single-source, on-patent brand: no generic empagliflozin can be sold at U.S. pharmacies, demand keeps growing as its approved uses expanded from diabetes to heart failure and chronic kidney disease, and list-price/rebate economics push the sticker price up. CMS put its 2023 list price at $573 for 30 days.
When will Jardiance go generic?
No U.S. generic launch date is certain. Empagliflozin's key patents remain in force into the late 2020s, and litigation or settlements will determine actual timing. Be skeptical of any site quoting a firm date.
What did Medicare negotiation do to Jardiance's price?
CMS negotiated Jardiance to $197 for a 30-day supply effective 2026, 66% below its 2023 list price of $573. That price applies within Medicare drug plans only.
Is there a cheaper drug that does what Jardiance does?
Other SGLT2 inhibitors are also brand-priced, and older diabetes generics like metformin ($3.95/month in our July 2026 snapshot) work differently and aren't substitutes you can swap yourself. Any regimen change is a prescriber decision.
Sources
Compare prices & find savings
This guide is for cost and savings education only. It is not medical advice. Talk to your doctor or pharmacist before making any changes to your medications. Prices vary by pharmacy, location, quantity, and eligibility, and they change over time.
Related guides
- Why Is My Medication So Expensive?
The real reasons a prescription can cost more than expected, from insurance tiers to PBM markups, plus what you can do about it.
- What Is a PBM? How Pharmacy Benefit Managers Affect Prices
Learn what a pharmacy benefit manager does, how PBMs shape drug prices and formularies, and what the FTC found about their role in the market.
- Patient Assistance Programs: Who Qualifies and How to Apply
How manufacturer and nonprofit patient assistance programs work, who typically qualifies by income, and what documents you need to apply.
- Medicare Part D Costs in 2026: The Out-of-Pocket Cap Explained
Learn how the $2,100 Medicare Part D out-of-pocket cap works in 2026, what counts toward it, and how it changed from prior years.